Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Thursday, May 15, 2008

MIT $100K judges pick Diagnostic-For-All

Diagnostic-For-All has won the MIT $100K Business Plan Competition, according to the school.

The nonprofit, an entrant in the biotechnology track, delivers affordable point-of-care diagnostic solutions in developing countries. The team's plan is based on patent-pending technology developed in chemist George Whitesides' laboratory at Harvard University. The tools are intended to be simple, portable, low-cost, and able to diagnose liver, kidney and metabolic diseases.

Diagnostic-For-All presented to a panel of judges including Gururaj "Desh" Deshpande, co-founder and chairman of Sycamore Networks Inc., and Robert Metcalfe, of Polaris Ventures.

The initial field of 232 entrants competed in seven categories. The category winners are:

This year's ceremony also included a live elevator pitch contest, voted on by the audience. The crowd voted using their mobile phones with technology from $100K mobile semi-finalist team Poll Everywhere. Covalent Solar, whose product is an MIT-invented solar concentrator photovoltaic technology, won the $10,000 prize.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.